Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Mankind Pharma has informed that the management and officials of the Company will be meeting with various investors in person in Singapore on August 14, 2024 to August 15, 2024. During the meeting with investors/analysts no unpublished price sensitive information (‘UPSI’) shall be disclosed which is not already available in public domain. The discussion would be based on the general business outlook and information which is already in public domain.
The above information is a part of company’s filings submitted to BSE.
